当前位置: 首页 >> 检索结果
共有 16281 条符合本次的查询结果, 用时 3.3920378 秒

141. Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.

作者: Fiona J Gilbert.;Nicholas R Payne.;Iris Allajbeu.;Lim Yit.;Sarah Vinnicombe.;Iain Lyburn.;Nisha Sharma.;Will Teh.;Jonathan James.;Archana Seth.;Tamara Suaris.;Reena Aggarwal.;Miaad Al-Attar.;Sarah Savaridas.;Antonis Antoniou.;Paul Pharoah.;Stephen Duffy.
来源: Lancet. 2025年405卷10493期1935-1944页
It is not known which supplemental imaging technique is most beneficial for women with dense breasts attending breast screening. This study compares abbreviated MRI, automated whole breast ultrasound (ABUS), and contrast-enhanced mammography versus standard of care in women with dense breasts and a negative mammogram. We report on interim results from the first round of supplemental imaging.

142. ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial.

作者: Raj R Makkar.;Ravi K Ramana.;Eric Gnall.;Basel Ramlawi.;Wen Cheng.;Pantelis Diamantouros.;Srinivasa Potluri.;Neal Kleinman.;Aakriti Gupta.;Tarun Chakravarty.;Sanjay Samy.;Andrew Rassi.;Vivek Rajagopal.;Steven Yakubov.;Paul Sorajja.;Dhairya Patel.;Santiago Garcia.;Pradeep Yadav.;Vinod Thourani.;John Wang.;Michael Rinaldi.;Samir Kapadia.;Ron Waksman.;John Webb.;Claire Ben Ren.;John Gregson.;Rodrigo Modolo.;Janarthanan Sathananthan.;Michael J Reardon.; .
来源: Lancet. 2025年405卷10494期2061-2074页
ACURATE neo2 is an open-cell, supra-annular, self-expanding transcatheter heart valve that is commercially available in over 50 countries but has not previously been evaluated in a randomised trial. ACURATE-IDE aimed to prospectively evaluate the safety and efficacy of transcatheter aortic valve replacement (TAVR) with the ACURATE neo2 valve compared with commercially available valves for the treatment of severe symptomatic aortic stenosis.

143. Announcing The Lancet Commission on Disability and Health: Creating disability-inclusive health systems that leave no one behind.

作者: Hannah Kuper.;Tom Shakespeare.;Winnie Mpanju-Shumbusho.; .
来源: Lancet. 2025年

144. Breast cancer screening at a crossroads: supplemental imaging for dense breasts.

作者: Nehmat Houssami.
来源: Lancet. 2025年405卷10493期1887-1889页

145. The missing link in the NCD agenda: girls and young women remain overlooked.

作者: Hamaiyal Sana.;Marie Hauerslev.;Muhammad Samsoor Zarak.;Kasisomayajula Viswanath.
来源: Lancet. 2025年405卷10493期1891-1893页

146. Starvation as a weapon of war in Gaza: violation of international law.

作者: Yara Ashour.;Abdallah Abu-Jlambo.;Samer Abuzerr.
来源: Lancet. 2025年405卷10494期2044页

147. Investing in adolescent health and wellbeing to secure sustainable progress.

作者: Tedros Adhanom Ghebreyesus.
来源: Lancet. 2025年405卷10493期1889-1891页

148. Moving the dial on diagnostics: an update from the Lancet Commission on diagnostics.

作者: Susan Horton.;Michael L Wilson.;Annie N Y Cheung.;Kristen DeStigter.;Mikashmi Kohli.;Shahin Sayed.;Lee F Schroeder.;Richard Sullivan.;Bien-Soo Tan.;Millicent Alooh.;Bernice Dahn.;Lluis Donoso-Bach.;Patricia J Garcia.;Sarwat Hussain.;Kekeletso Kao.;Lai-Meng Looi.;Madhukar Pai.;Mario Plebani.;Yenew Kebede Tebeje.;Grace Umutesi.;Kamini Walia.;Kenneth A Fleming.
来源: Lancet. 2025年405卷10496期2241-2254页
The Lancet Commission on diagnostics made recommendations for ten topics: national strategy (including national essential diagnostics lists), access in primary care, workforce, regulatory framework, national financing, affordability, appropriate use of technology, needs in conflict or fragile situations, advocacy, and an international alliance with oversight capabilities. Since 2021, progress in these areas has benefitted greatly from the adoption of a World Health Assembly resolution on diagnostics and the work of a broad coalition, as assessed by literature surveys by subject matter experts, quantitative findings (where feasible), and an anonymous survey of knowledgeable and engaged individuals. Greater progress was observed where there was political will and the production of diagnostics coincided with industrial policy goals, also in areas where changing the legal and health policy frameworks was involved. Progress was slower on recommendations with substantial resource implications (eg, labour force, affordability, and diagnostics for conflict situations). It is expected that the Global Diagnostics Coalition will consolidate and accelerate progress.

149. Sarah Baird: understanding, action, and optimism.

作者: Niall Boyce.
来源: Lancet. 2025年

150. A wake-up call: the second Commission on adolescent health.

作者: The Lancet.
来源: Lancet. 2025年405卷10493期1883页

151. A call to action: the second Lancet Commission on adolescent health and wellbeing.

作者: Sarah Baird.;Shakira Choonara.;Peter S Azzopardi.;Prerna Banati.;Judith Bessant.;Olivia Biermann.;Anthony Capon.;Mariam Claeson.;Pamela Y Collins.;Nicole De Wet-Billings.;Surabhi Dogra.;Yanhui Dong.;Kate L Francis.;Luwam T Gebrekristos.;Allison K Groves.;Simon I Hay.;David Imbago-Jácome.;Aaron P Jenkins.;Caroline W Kabiru.;Elissa C Kennedy.;Luo Li.;Chunling Lu.;Jun Ma.;Terry McGovern.;Augustina Mensa-Kwao.;Sanyu A Mojola.;Jason M Nagata.;Adesola O Olumide.;Olayinka Omigbodun.;Molly O'Sullivan.;Audrey Prost.;Jennifer H Requejo.;Yusra R Shawar.;Jeremy Shiffman.;Avi Silverman.;Yi Song.;Sharlene Swartz.;Rita Tamambang.;Henrik Urdal.;Joseph L Ward.;George C Patton.;Susan M Sawyer.;Alex Ezeh.;Russell M Viner.
来源: Lancet. 2025年405卷10493期1945-2022页

152. A new definition of human health is needed to better implement One Health.

作者: Thierry Lefrançois.;Jean-Luc Angot.;Brigitte Autran.;Salome A Bukachi.;Elisabeth Claverie de Saint-Martin.;Patrick Giraudoux.;Estelle Lefrançois.;Bruno Lina.;Khuat Thi Hai Oanh.;David O Obura.;Jean-François Delfraissy.
来源: Lancet. 2025年

153. A pillar of Brazilian public health: Fiocruz at 125.

作者: Lise Alves.
来源: Lancet. 2025年

154. Ending nuclear weapons, before they end us.

作者: Kamran Abbasi.;Parveen Ali.;Virginia Barbour.;Marion Birch.;Inga Blum.;Peter Doherty.;Andy Haines.;Ira Helfand.;Richard Horton.;Kati Juva.;Jose F Lapena.;Robert Mash.;Olga Mironova.;Arun Mitra.;Carlos Monteiro.;Elena N Naumova.;David Onazi.;Tilman Ruff.;Peush Sahni.;James Tumwine.;Carlos Umaña.;Paul Yonga.;Chris Zielinski.
来源: Lancet. 2025年405卷10497期2262-2264页

155. Dietary energy in balance: time for an update of energy requirements.

作者: L M Neufeld.;C U Loechl.
来源: Lancet. 2025年405卷10494期2030-2032页

156. The potential impact of the Trump administration policies on health research in the USA.

作者: Steven H Woolf.;Sandro Galea.;David R Williams.
来源: Lancet. 2025年405卷10495期2114-2116页

157. Safely lowering triglycerides through ANGPTL4 inhibition.

作者: Anders B Wulff.
来源: Lancet. 2025年405卷10493期1885-1887页

158. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.

作者: Beryl B Cummings.;Mark P Joing.;Page R Bouchard.;Mark N Milton.;Peter F Moesta.;Vyas Ramanan.;Andrew Lane.;Joe Hirman.;John W Trauger.;Eleftheria Maratos-Flier.;Andrei Voznesensky.;Igor Splawski.;Amitabh V Nimonkar.;Meghan M Flaherty.;B Alexander Yi.;Daniel Meyers.;Francois Huet.;Sukhdeep K Sahambi.;Denise P Yates.;Douglas Hom.;Markus Hinder.;Craig T Basson.;Chris O'Donnell.;Evan S Siegelman.;Chris E Garrett.;Joshua Lehrer-Graiwer.;Rebecca A Juliano.;Ethan J Weiss.
来源: Lancet. 2025年405卷10493期1923-1934页
Genetic studies have established angiopoietin-related protein 4 (ANGPTL4) as a key regulator of triglyceride metabolism and a promising target to reduce atherosclerotic cardiovascular disease (ASCVD) risk beyond traditional risk factors. Human ANGPTL4 loss-of-function shows no adverse consequences and is associated with reduced triglycerides and remnant cholesterol, and a reduced risk of type 2 diabetes and ASCVD. Nonetheless, development of ANGPTL4 inhibitors has been delayed due to adverse findings in ANGPTL4-knockout mice fed a high saturated fat diet, including lipid accumulation in mesenteric lymph nodes, systemic inflammation, adverse clinical signs, and reduced survival. We previously reported the development and preclinical characterisation of MAR001, an ANGPTL4 inhibitory antibody. Here, we report a comprehensive safety assessment of ANGPTL4 inhibition, including novel analysis of genetic ANGPTL4 loss on mesenteric lymph node architecture in humans and two early-phase clinical trials.

159. Clozapine: old drugs require efforts to improve patient experience and access.

作者: Jack B Fanshawe.;Thomas Kabir.;Belinda R Lennox.
来源: Lancet. 2025年405卷10497期2259-2261页

160. Opportunities for chronic pain self-management: core psychological principles and neurobiological underpinnings.

作者: Lene Vase.;Tor D Wager.;Christopher Eccleston.
来源: Lancet. 2025年405卷10491期1781-1790页
One in five of the population lives with chronic pain. Psychological interventions for pain reveal core principles that can be used to create opportunities for chronic pain self-management in primary practice, across health-care settings, and at home. We highlight the different types of chronic pain and illustrate the psychoneurobiological mechanisms involved. We review core principles for psychological pain management, evaluate the evidence, and illustrate the underlying neurobiology involved. We provide practical advice for how to facilitate pain self-management in clinical practice. Finally, we discuss scientific caveats and practical obstacles to improvement, suggesting possible pathways to implementation.
共有 16281 条符合本次的查询结果, 用时 3.3920378 秒